Brokerages Set Monopar Therapeutics Inc. (NASDAQ:MNPR) Target Price at $118.67

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $118.6667.

A number of research firms recently weighed in on MNPR. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. HC Wainwright increased their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Finally, Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $109.00 to $119.00 in a research report on Thursday, August 13th.

Monopar Therapeutics Stock Up 3.4%

Shares of NASDAQ MNPR opened at $111.36 on Friday. The business’s 50 day moving average price is $102.67 and its two-hundred day moving average price is $73.58. The company has a market cap of $747.23 million, a PE ratio of -51.32 and a beta of 1.47. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. As a group, research analysts anticipate that Monopar Therapeutics will post -2.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MNPR. Siren L.L.C. boosted its holdings in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after purchasing an additional 13,761 shares during the period. Walleye Capital LLC acquired a new stake in Monopar Therapeutics during the 1st quarter worth approximately $3,458,000. Finally, Virtu Financial LLC acquired a new stake in Monopar Therapeutics during the 4th quarter worth approximately $654,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.